According to the Wall St. Journal, the National Institutes of Health has decided to ease some of the restrictions it put in place earlier this year, including easing its rules on stock ownership:
The rules will allow senior NIH employees and their immediate families to hold up to $15,000 of stock in individual pharmaceutical and biotechnology companies, as well as up to $50,000 in health-care sector funds. The original rules proposed banning top NIH employees from holding stock in any pharmaceutical and biotech companies and limiting the stock holdings of other lower-level employees.
The article doesn't mention whether this easing of the rules will apply to NIH staff's ability to participate in outside CME, though. Be curious to see how this develops.